179 related articles for article (PubMed ID: 35490314)
1. Interactions Between Meropenem and Renal Drug Transporters.
Dong J; Liu Y; Li L; Ding Y; Qian J; Jiao Z
Curr Drug Metab; 2022 Aug; 23(5):423-431. PubMed ID: 35490314
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
3. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
4. Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions.
Li W; Jiao Z; Liu Y; Yao J; Li G; Dong J
Eur J Pharm Sci; 2021 Jul; 162():105814. PubMed ID: 33753216
[TBL] [Abstract][Full Text] [Related]
5. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
[TBL] [Abstract][Full Text] [Related]
6. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
7. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
[TBL] [Abstract][Full Text] [Related]
8. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
[TBL] [Abstract][Full Text] [Related]
9. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.
McCormick A; Swaisland H
Xenobiotica; 2017 Oct; 47(10):903-915. PubMed ID: 27684210
[TBL] [Abstract][Full Text] [Related]
10. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
Tong Z; Yerramilli U; Surapaneni S; Kumar G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):869-74. PubMed ID: 24627218
[TBL] [Abstract][Full Text] [Related]
11. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.
Fujioka K; Fekry MI; Rumsey JM; Steiner T; Thompson D; Mousa SA
Clin Transl Sci; 2023 Jun; 16(6):987-1001. PubMed ID: 36967488
[TBL] [Abstract][Full Text] [Related]
12. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1).
Lai Y; Sampson KE; Balogh LM; Brayman TG; Cox SR; Adams WJ; Kumar V; Stevens JC
J Pharmacol Exp Ther; 2010 Sep; 334(3):936-44. PubMed ID: 20519552
[TBL] [Abstract][Full Text] [Related]
15. Transporter-mediated Natural Product-Drug Interactions.
Bi Y; Wang X; Ding H; He F; Han L; Zhang Y
Planta Med; 2023 Feb; 89(2):119-133. PubMed ID: 35304735
[TBL] [Abstract][Full Text] [Related]
16. Differential interactions of the β-lactam cloxacillin with human renal organic anion transporters (OATs).
Lalanne S; Le Vée M; Lemaitre F; Le Corre P; Verdier MC; Fardel O
Fundam Clin Pharmacol; 2020 Aug; 34(4):476-483. PubMed ID: 32100322
[TBL] [Abstract][Full Text] [Related]
17. Transporter-mediated drug-drug interactions.
Müller F; Fromm MF
Pharmacogenomics; 2011 Jul; 12(7):1017-37. PubMed ID: 21787191
[TBL] [Abstract][Full Text] [Related]
18. Age-associated differences in transporter gene expression in kidneys of male rats.
Xu YJ; Wang Y; Lu YF; Xu SF; Wu Q; Liu J
Mol Med Rep; 2017 Jan; 15(1):474-482. PubMed ID: 27909713
[TBL] [Abstract][Full Text] [Related]
19. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
20. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]